Benitec Biopharma Limited (NASDAQ:BNTC) Stock Has Consensus Price Target of $22.00 According to Brokerages

Shares of Benitec Biopharma Limited (NASDAQ:BNTC) have been given a consensus rating of “Moderate Buy” by the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $22.00.

BNTC has been the subject of a number of analyst reports. Citigroup reiterated a “market outperform” rating on shares of Benitec Biopharma in a research report on Tuesday, October 6th. Royal Bank Of Canada upgraded Benitec Biopharma to an “outperform” rating in a research report on Tuesday, September 15th. HC Wainwright reaffirmed a “buy” rating on shares of Benitec Biopharma in a report on Monday, November 2nd. Raymond James Financial initiated coverage on Benitec Biopharma in a research report on Friday, October 23rd. They set an “outperform” rating and a $14.00 price target on the stock. Finally, Wall Street Zen lowered Benitec Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, September 19th.

Benitec Biopharma Price Performance

Shares of BNTC opened at $9.54 on Thursday. The stock has a market capitalization of $332.85 million, a price-to-earnings ratio of -9.73 and a beta of 0.26. Benitec Biopharma has a 1 year low of $7.89 and a 1 year high of $14.39. The business’s 50 day simple moving average is $9.98 and its 200-day simple moving average is $11.47.

Benitec Biopharma (NASDAQ:BNTC) last posted its earnings results on Monday, September 14th. The biotechnology company reported ($0.26) earnings per share for the quarter, meeting the consensus estimate of ($0.26). On average, sell-side analysts expect that Benitec Biopharma will post -1.35 earnings per share for the current year.

Institutional Trading of Benitec Biopharma

Large investors have recently made changes to their positions in the company. AWM Investment Company Inc. acquired a new stake in shares of Benitec Biopharma in the second quarter valued at $2,515,000. Bank of New York Mellon Corp purchased a new stake in Benitec Biopharma during the 2nd quarter worth about $804,000. ADAR1 Capital Management LLC acquired a new stake in Benitec Biopharma in the 1st quarter valued at about $186,000. Bank of America Corp DE raised its position in Benitec Biopharma by 43.3% in the 1st quarter. Bank of America Corp DE now owns 17,376 shares of the biotechnology company’s stock valued at $185,000 after purchasing an additional 5,251 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Benitec Biopharma by 18.7% in the 2nd quarter. GAMMA Investing LLC now owns 7,961 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 1,256 shares during the last quarter. 52.19% of the stock is currently owned by hedge funds and other institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Inc (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines based on its proprietary DNA-directed RNA interference (ddRNAi) technology. The platform is designed to enable cells to produce small hairpin RNA molecules that can selectively reduce the expression of disease-causing genes, potentially providing longer-lasting gene silencing than conventional RNA-based approaches.

The company’s lead program is BB-301, an investigational gene therapy being developed for oculopharyngeal muscular dystrophy type 1 (OPMD1), a rare inherited disorder that affects muscles involved in swallowing and movement.